The large numbers of adults with dyslipidemia in the seven major markets can be directly attributed to lifestyle choices, such as high caloric intake and limited physical activity. There is a clear disparity between the number of total prevalent cases and diagnosed cases, as well as a failure to properly manage the disease in all patients.
Features and benefits
Highlights
Datamonitor expects to see an excessive, but stable, number of prevalent cases of dyslipidemia in all of the seven major markets, with the majority of cases seen in the US and Germany. Between 2011 and 2021, Datamonitor forecasts dyslipidemia prevalent cases in the seven major markets to increase by only 0.7%.
Between 2011 and 2021, Datamonitor forecasts prevalent cases of dyslipidemia in the seven major markets will remain stable, increasing from 123.9 million cases in 2011 to 132.5 million prevalent cases in 2021. Each of the seven major markets will experience marginal increases in prevalent dyslipidemia cases (0.1% to 1.2%) between 2011 and 2021.
No. of Pages: 31
Price: Single User License: US$ 5700 Corporate User License: US$ 14250
Your key questions answered
OVERVIEW
EXECUTIVE SUMMARY
DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
GLOBAL VARIATION AND HISTORICAL TRENDS
DRIVERS OF DYSLIPIDEMIA EPIDEMIOLOGY
EPIDEMIOLOGIC FORECASTING OF DYSLIPIDEMIA
EPIDEMIOLOGIC RESULTS
DISCUSSION
BIBLIOGRAPHY
APPENDIX
List Of Tables
List Of Figures
Features and benefits
- Gain insight into market potential, including a robust 10-year epidemiology forecast of dyslipidemia prevalent cases.
- Understand the key epidemiologic risk factors associated with dyslipidemia.
Highlights
Datamonitor expects to see an excessive, but stable, number of prevalent cases of dyslipidemia in all of the seven major markets, with the majority of cases seen in the US and Germany. Between 2011 and 2021, Datamonitor forecasts dyslipidemia prevalent cases in the seven major markets to increase by only 0.7%.
Between 2011 and 2021, Datamonitor forecasts prevalent cases of dyslipidemia in the seven major markets will remain stable, increasing from 123.9 million cases in 2011 to 132.5 million prevalent cases in 2021. Each of the seven major markets will experience marginal increases in prevalent dyslipidemia cases (0.1% to 1.2%) between 2011 and 2021.
Dyslipidemia Epidemiology Market
Published: February 2012No. of Pages: 31
Price: Single User License: US$ 5700 Corporate User License: US$ 14250
Your key questions answered
- What are the most robust sources for dyslipidemia prevalence data?
- How will the patient population change over the next decade in the seven major markets?
- What are the major risk factors for dyslipidemia that are driving the trend in prevalent cases and how are they changing?
OVERVIEW
EXECUTIVE SUMMARY
DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
GLOBAL VARIATION AND HISTORICAL TRENDS
DRIVERS OF DYSLIPIDEMIA EPIDEMIOLOGY
EPIDEMIOLOGIC FORECASTING OF DYSLIPIDEMIA
EPIDEMIOLOGIC RESULTS
DISCUSSION
BIBLIOGRAPHY
APPENDIX
List Of Tables
List Of Figures
